Literature DB >> 12909741

Novel gene therapy approaches to pancreatic cancer.

Matthew H Katz1, Michael Bouvet.   

Abstract

One of the most lethal human malignancies, pancreatic adenocarcinoma has remained a therapeutic challenge. Historically, the only curable treatment modalities available to patients with this disease have included pancreaticoduodenectomy with adjuvant chemoradiation. Few patients, however, have resectable disease at the time of presentation, and even for those who are offered this radical course of treatment, post-surgical survival is dismally short. Recently, however, advances in the understanding of the molecular biology of pancreatic cancer have enabled researchers to investigate novel gene therapy approaches to the treatment of this disease. In this paper, we review the common genetic mutations found in pancreatic adenocarcinomas, discuss strategies for the manipulation of genetic targets, and assess current progress in the field of gene therapy as it relates to pancreatic cancer.

Entities:  

Mesh:

Year:  2003        PMID: 12909741     DOI: 10.1385/IJGC:33:1:89

Source DB:  PubMed          Journal:  Int J Gastrointest Cancer        ISSN: 1537-3649


  61 in total

1.  Cancer. A deadly inheritance.

Authors:  B Vogelstein
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

2.  K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster.

Authors:  W L Cerny; K A Mangold; D G Scarpelli
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

3.  Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA.

Authors:  T Mukhopadhyay; M Tainsky; A C Cavender; J A Roth
Journal:  Cancer Res       Date:  1991-03-15       Impact factor: 12.701

4.  Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors.

Authors:  A Block; S H Chen; K Kosai; M Finegold; S L Woo
Journal:  Pancreas       Date:  1997-07       Impact factor: 3.327

5.  Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus.

Authors:  U S Joshi; S T Dergham; Y Q Chen; M C Dugan; J D Crissman; V K Vaitkevicius; F H Sarkar
Journal:  Pancreas       Date:  1998-03       Impact factor: 3.327

Review 6.  Gene therapy for cancer: what have we done and where are we going?

Authors:  J A Roth; R J Cristiano
Journal:  J Natl Cancer Inst       Date:  1997-01-01       Impact factor: 13.506

7.  Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo.

Authors:  A S Rigg; N R Lemoine
Journal:  Cancer Gene Ther       Date:  2001-11       Impact factor: 5.987

8.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.

Authors:  M S Redston; C Caldas; A B Seymour; R H Hruban; L da Costa; C J Yeo; S E Kern
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

9.  In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta.

Authors:  G R Peplinski; K Tsung; J B Meko; J A Norton
Journal:  Surgery       Date:  1995-08       Impact factor: 3.982

10.  High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus.

Authors:  W W Zhang; X Fang; W Mazur; B A French; R N Georges; J A Roth
Journal:  Cancer Gene Ther       Date:  1994-03       Impact factor: 5.987

View more
  1 in total

1.  Metabonomic studies of pancreatic cancer response to radiotherapy in a mouse xenograft model using magnetic resonance spectroscopy and principal components analysis.

Authors:  Xin-Hong He; Wen-Tao Li; Ya-Jia Gu; Bao-Feng Yang; Hui-Wen Deng; Yi-Hua Yu; Wei-Jun Peng
Journal:  World J Gastroenterol       Date:  2013-07-14       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.